This study aims to determine if traditional markers of disadvantage [female sex, low socio-economic status (SES), and remoteness] are associated with lower prescription of evidence-based therapy and higher mortality among patients with moderate-severe heart failure with reduced ejection fraction.
Introduction
Disparity in health status and the delivery of evidence-based treatment for cardiovascular disease based on sex and socio-economic status (SES) is extremely concerning. 1 Gender inequality in the treatment and outcomes post-acute coronary syndrome has been extensively reported in the medical literature 2,3 as has a marked female predominance in the incidence of heart failure with preserved ejection fraction. 4, 5 The same cannot be said for heart failure with reduced ejection fraction (HFrEF). While older trials have not shown a higher mortality among women with HFrEF, 6 there is a lack of recent data on outcomes in women with HFrEF, especially non-ischaemic cardiomyopathy (NICM) alone. This may be due to the fact that only 24% of those enrolled in pure HFrEF trials are women, 7 despite accounting for 35-50% of HFrEF diagnoses. 8 As a result, there are no sex-specific heart failure guidelines 9 even though there are known differences in response to cardiovascular drugs. 10 Socio-economic status describes a person's access to material and social resources as well as their ability to participate in society. It is often measured as a combination of education, income, and occupation. SES is a key factor in determining quality of life for women 11 and a known determinant of poor outcomes 12 and a lack of access to evidence-based treatment 13 in heart failure patients. Similarly, living in a rural setting has been associated with poorer health and a decrease in uptake of heart failure therapies. 14 We sought to investigate whether prescription of evidence-based therapies and defibrillator implantation was equal regardless of gender, SES, and remoteness in a contemporary Australian cohort of patients with moderatesevere HFrEF and to determine if this has an effect on survival.
Methods
This was a post hoc analysis of data collected for a recently published trial that evaluated the reduction in mortality from implantable cardioverter-defibrillators (ICDs) in NICM patients. 15 Methods have been described previously, but in brief, New York Heart Association (NYHA) class II-III patients with non-ischaemic systolic heart failure and a left ventricular ejection fraction (LVEF) ≤35% were recruited from The Alfred Hospital, Victoria, Australia, between 2005 and 2016. All patients underwent cardiac magnetic resonance imaging (CMR), and only those with NICM were eligible. Exclusion criteria included an ischaemic pattern of scar on CMR, complex congenital heart disease, prior ventricular fibrillation or sustained ventricular tachycardia, and severe valvular disease requiring intervention in the follow-up period. Patients with ischaemic cardiomyopathy were defined as having segmental wall motion abnormalities or wall thinning in a particular coronary territory with subendocardial or transmural late gadolinium enhancement. Patients with severe left ventricular dysfunction and a small amount of ischaemic late gadolinium enhancement (i.e. an infarct out of keeping with the amount of left ventricular dysfunction) were included only if a recent coronary angiogram without obstructive coronary disease (defined as ≥70% stenosis in any major epicardial vessel or sub-branch) or a negative functional study was performed. There were 6788 CMR studies performed during the study period from which we identified 888 patients with an LVEF ≤35%. Four hundred and fifty-two patients were eligible for inclusion. The Alfred ethics committee and The Baker Heart and Diabetes Institute Clinical Governance Unit approved the study.
Measures of socio-economic status
Each patient's residential address was used to determine SES. We used the Index of Relative Socio-economic Advantage and Disadvantage (IRSAD) generated by the Australia Bureau of Statistics. 16 The IRSAD ranks areas in terms of relative socio-economic advantage and disadvantage on a continuum from most disadvantaged (1) to most advantaged (5) . A multidimensional framework to guide the variable selection process is used. The dimensions included were income variables, education variables, employment variables, occupation variables, housing variables, and other miscellaneous indicators of relative advantage or disadvantage (see Appendix 1 for a full list of variables and their weighting).
We also investigated how living remotely may influence the outcomes of interest. The Accessibility/Remoteness Index of Australia (ARIA) is an unambiguously geographical approach to defining remoteness. 17 Geographic remoteness is essentially a measure of a physical location's level of access to goods and services. Large population centres tend to have a greater range of goods and services available than small centres. The lower the ARIA score for a location, the better its level of access to goods and services. Socio-economic, urban/rural, and population size factors are not considered for incorporation into the measure. There are four categories (major cities, inner regional, outer regional, and remote and/or very remote area). Victoria is the most densely populated state in Australia with a lower rate of residence in outer regional, remote, and very remote areas. Given the majority of our cohort resided in Victoria, we classified our patients into two categories:
(1) ARIA index value 0-2.4 (major cities of Australia and inner regional Australia). (2) ARIA index value >2.4 (outer regional Australia, remote Australia, and very remote Australia).
Baseline clinical and demographic data
Baseline demographic and clinical data, including sex and address, were recorded in all patients at the time of CMR. The presence and date of implantation of ICD devices were recorded for the entire follow-up period.
Medical and device therapy
Evidence-based medical therapies included in the analysis were drugs and ICD. The decision to prescribe medications and implant an ICD was according to the institutional guidelines of the treating centre based on the guidelines for the prevention, detection, and management of people with chronic heart failure in Australia. 18 All patients who received an ICD in the follow-up period were analysed as part of the ICD group.
Definition of endpoints
The primary outcome was all-cause mortality based on sex, and the secondary outcomes were all-cause mortality based on SES and remoteness, cardiovascular mortality based on sex, SES, and remoteness, and prescription of beta-blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and aldosterone antagonists based on sex, SES, and remoteness. All-cause mortality was defined as any cause of death. Cardiovascular cause of death was defined as death attributable to myocardial ischaemia and infarction, heart failure, or cardiac arrest because of other or unknown cause. Cause of death was obtained from the death certificate. The medical records were reviewed, and if the requisite information was not available, the Department of Births, Deaths and Marriages was contacted. Duration of follow-up was calculated from the baseline scan until last patient contact or occurrence of an endpoint. Table 1) .
Statistical analysis
Thirty-six (8%) patients had an IRSAD score of 1 (most disadvantaged quintile relative to the Australia population), 64 (14.2%) patients had an IRSAD score of 2 (2nd most disadvantaged quintile relative to the Australia population), 110 (24.3%) patients had an IRSAD score of 3 (3rd most disadvantaged quintile relative to the Australia population), 127 (28.1%) patients had an IRSAD score of 4 (2nd most advantaged quintile relative to the Australian population), and 115 (25.4%) patients had an IRSAD score of 5 (most advantaged quintile relative to the Australian population). The same baseline characteristics shown in Table 1 were compared over the IRSAD groups. There were no significant differences in baseline characteristics between the IRSAD groups.
Three hundred and eighty-four (85%) patients had an ARIA index value 0-2.4. Sixty-eight (15%) patients had an ARIA score of >2.4. The same baseline characteristics shown in Table 1 were compared over the ARIA groups. All other variables were the same across the groups. 
Outcomes according to sex
Fifty-one (53%) women underwent ICD insertion, which was not significantly different, compared with the 195 (57%) men that underwent ICD insertion [χ 2 (1) = 0.35, 0.56] [ Figure 1A ]. Similarly, there was no difference in rate of beta-blocker therapy; 80 (73%) women received beta-blockers compared with 257 (75%) men [χ 2 (1) = 0.91, 0.66] [ Figure 1B ]. Eighty-five (78%) women received ACE inhibitors, which was identical to the rate in the 268 (78%) men [χ 2 (1) = 0.001, 0.97] [ Figure 1C ]. In addition, the rate of aldosterone antagonists was similar with 39 (36%) women receiving aldosterone antagonists compared with 126 (37%) men [χ 2 (1) = 2.71, 0.10] [ Figure 1D ]. Twenty-five (23%) women and 52 (15%) men died during the study. There was no difference in overall survival based on sex [HR = 1.19, 95% confidence interval (CI): 0.74-1.92, 0.48] [ Figure 2A ]. Sixteen (64%) of the deaths in women were attributed to a cardiovascular cause, which was no difference compared with the 33 (63%) cardiovascular deaths in men (HR = 0.88, 95% CI: 0.49-1.61, 0.63) [ Figure 2B ].
Outcomes according to socio-economic status
Twenty-four (66.7%) patients with an IRSAD score of 1 received an ICD compared with 38 (59.3%) patients with an IRSAD score of 2, 54 (49%) patients with an IRSAD score of 3, 75 (59%) patients with an IRSAD score of 4, and 54 (49.0%) patients with an IRSAD score of 5. There was no difference between the rate of ICD insertion based on SES [χ 2 (4) = 7.53, 0.11] (Supporting Information, Figure S1A ). In addition, there was no difference between rates of beta-blockers [χ 2 (4) = 3.43, 0.49] (Supporting Information, Figure S1B ), ACE inhibitor/ARB [χ 2 (4) = 1.77, 0.78] (Supporting Information, Figure S1C ), and aldosterone antagonist [χ 2 (4) = 3.91, 0.42] (Supporting Information, Figure S1D ) prescription based on SES. There were no differences in overall [ Figure 3A ] nor cardiovascular mortality [ Figure 3B ] based on SES.
Outcomes according to remoteness
Two hundred and seven (53.9%) patients living in a major city or inner regional area underwent ICD implantation compared with 38 (55.9%) in outer regional and rural areas. There was no difference between rates of ICD implantation according to ARIA [χ 2 (1) = 0.078, 0.78] [ Figure 4A ]. Two hundred and ninety-nine (77.8%) patients in major cities/inner regional areas received beta-blockers compared with 38 (55.9%) in outer regional and remote areas. Three hundred and nine (80.5%) patients in major cities/inner regional areas received ACE inhibitors/ARBs compared with 44 (64.7%) living remotely. Patients living more remotely were less likely to receive beta-blockers [χ 2 (1) = 14.72, P < 0.001] [ Figure 4B ] and Figure 4C ] compared with their city counterparts. There was no difference in prescription of aldosterone antagonists based on place of residence [χ 2 (1) = 0.60, 0.44] [ Figure 4D ].
There were 63 (16%) deaths in the group with an ARIA score of 0-2.4, 43 (68%) of which were due to a cardiovascular cause. There were 14 (21%) deaths in those with an ARIA score >2.4, six (42%) of which were due to a cardiovascular cause. There was no difference in overall (HR = 1.15, 95% CI: 0.64-2.05, 0.64) [ Figure 5A ] nor cardiovascular mortality (HR = 0.71, 95% CI: 0.30-1.68, 0.44) [ Figure 5B ] based on place of residence.
The interaction between gender, remoteness, and SES was tested, and there was no evidence of an interaction.
Discussion
The findings from our study are the following. First, in HFrEF, due to NICM, there is no effect of sex on either all-cause or cardiovascular mortality. Second, rates of prescription of evidence-based therapies are equal in this cohort of patients with moderate-severely reduced EF. We observed the same trend when patients were analysed according to SES and Sex, socio-economic status, and remoteness impact therapy and survival in heart failure place of residence. Taken together, we believe that when treatment is equal, many of the factors leading to worse outcomes in disadvantaged patients are mitigated.
Data from the Framingham study suggest that all-cause mortality from heart failure is decreasing. 19 Some studies have shown a parallel decrease in mortality in both sexes 20 or even improved outcomes in women, especially in NICM. 6, 21, 22 Unfortunately, it has also been reported that this positive trend exists in men but not in women. 23 Although parity in the prescription of heart failure therapies in the sexes has been documented, 24 under prescription of evidence-based medications also exists 25 and has been postulated as a reason for worse outcomes in women. Our data suggest that when tangible evidence of significant cardiac dysfunction exists (i.e. severely reduced ejection fraction), delivery of evidence-based therapy is equal. This resulted in near identical survival between groups based on factors traditionally thought to worsen outcomes in cardiovascular conditions. A similar phenomenon has been reported in a systematic review of cardiac resynchronization therapy trials 26 -although women are markedly under-represented in cardiac resynchronization therapy trials, when a cardiac resynchronization therapy device is implanted, women have a therapeutic response that is equivalent to or better than in men. Similarly, despite lower rates of ICD implantation in women in the USA compared with men, 27 it has been shown that when access to treatment and counselling around ICD implantation is equal between the sexes, rates of ICD implantation are also equal. 28 The intersectionality of sex and low SES drives poor outcomes in many disease states. Low SES has consistently been associated with worse outcomes in heart failure; however, this has tended to occur in tandem with lower rates of prescription of evidence-based therapy. 29 Our data suggest that when guidelines are followed equally stringently among socio-economic groups, outcomes are equal.
Remote residence is arguably the most problematic barrier in delivery of health services. Even in countries where other markers of disadvantage are overcome, longer distances to heath care centres and decreased physician density seem to be insurmountable obstacles. 30 Our study demonstrated lower rates of beta-blocker and ACE inhibitor/ARB therapy among those living more remotely. Although there was no difference in overall nor cardiovascular mortality based on place of residence, due to the population distribution in Victoria, only 68 patients were classified as living in outer regional and remote areas, and survival differences may have been borne out in a larger cohort.
Limitations
All patients in our cohort had NICM. While this narrows theapplicability of the data, the inclusion of patients with ischaemic cardiomyopathy adds potentially complicating factors into the analysis. Women are known to have worse outcomes for women post-acute coronary syndrome and reduced rates of revascularization and appropriate medical therapy 3 ; in addition, the role of revascularization in ischaemic cardiomyopathy has previously been controversial. 31 NICM, conversely, has a discrete amount of evidence-based treatments that can be delivered, allowing for a clearer dataset to examine equity in health. Although most trials examining the outcomes according to sex in HFrEF have included pre-specified analyses on the NICM group, 6 we believe that this is the only trial to exclude ischaemic cardiomyopathy using CMR, and therefore, we present findings in a unique cohort.
Only 24% of our patients were women; however, this is reflective of the number of women enrolled in other heart failure trials. 32 Finally, although data were collected prospectively, this was a post hoc analysis of an observational trial and is therefore subject to confounders.
In conclusion, equality in delivery of evidence-based therapy in women and the underprivileged may be the answer to improving mortality in these traditionally disadvantaged groups. Those living in the most remote areas still have lower rates of prescription-based therapy; however, this did not effect outcomes in this study.
Supporting information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Figure S1 . Association between SES and evidence based therapy. There was no difference in rates of ICD implantation (A), nor prescription of beta-blockers (B), ACE inhibitors/ARBs (C) and angiotensin receptor antagonists (D) based on SES status.
